8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Apr 3, 2026·SEC
Advanced Biomed Inc. Common Stock(ADVB)Earnings, Financials & Key Ratios
ADVB•NASDAQ
$4.49
Price updated Jun 27, 2026
AboutAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$83K+96.1%
- Net Income-$102K+96.4%
- EPS (Diluted)-0.16-23.1%
- ROE-0.01%+100.0%
ADVB Price & Volume
Advanced Biomed Inc. Common Stock (ADVB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Masks Structural Capital Erosion
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Mixed
Cash Flow:Burning
Primary Risk:Pre-revenue clinical execution risk
Key Thesis Takeaways
- Advanced Biomed Inc.
- remains a high-risk, pre-commercial entity characterized by a total absence of revenue over the last ten quarters and significant volatility in its operational performance.
- While the company maintains a current ratio of 7.38 as of 2026Q3, the rapid contraction of total assets from $8.3 million in 2025Q3 to $333.0K suggests a precarious path toward commercialization.
- Investors should monitor the company's ability to pivot from its current cash-burning diagnostic clinic model toward a sustainable revenue-generating platform, given the deep deficit in retained earnings of $414.5K.
Verdict Logic
the company's persistent pre-revenue status and the erosion of its asset base to $333.0K in 2026Q3 present an unacceptable risk profile for institutional capital allocation.
ADVB Growth Metrics
Advanced Biomed Inc. Common Stock (ADVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM91.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM256.86%
Return on Capital
10 Years-115.41%
5 Years-115.41%
3 Years-96.07%
Last Year-0.01%
ADVB Recent Earnings
Advanced Biomed Inc. Common Stock (ADVB) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.38
—
Rev
—
—
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.32
—
Rev
—
—
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$0.02
—
Rev
—
—
Q4 2025
Oct 8, 2025Metric
Actual
Est
EPS
$0.03
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.38 | — |
| Q1 2026 | Feb 13, 2026 | $0.32 | — |
| Q4 2025 | Nov 19, 2025 | $0.02 | — |
| Q4 2025 | Oct 8, 2025 | $0.03 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Advanced Biomed Inc. Common Stock (ADVB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.49 | $5.77M | -28.06 | — | — | -0.01% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $10.99 | $351.66M | 4.78 | 6774.96% | -256.6% | -17.04% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — |
Compare ADVB vs Peers
Advanced Biomed Inc. Common Stock (ADVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADVB SEC Filings & Documents
Advanced Biomed Inc. Common Stock (ADVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ADVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADVB Frequently Asked Questions
Advanced Biomed Inc. Common Stock (ADVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ADVB profitable?
Advanced Biomed Inc. Common Stock (ADVB) reported a net loss of $0.2M for fiscal year 2025.
Dividend & Returns
What is ADVB's return on equity?
Advanced Biomed Inc. Common Stock (ADVB) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
What is Advanced Biomed Inc. Common Stock's free cash flow?
Advanced Biomed Inc. Common Stock (ADVB) had negative free cash flow of $0.1M in fiscal year 2025, likely due to heavy capital investments.